COMP <GO>
CARR vs TMO // EV/EBITDA & P/E VALUATION
Carrier Global Corporation Common Stock (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: CARR 5
— TMO 9
▲ EV/EBITDA & P/E VALUATION LEADER: CARR
LAST: $53.63 (-3.44%) • MKT CAP: $45.78B
valuation
18.5x
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
valuation
30.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CARR VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CARR | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 41.00% | 0.00 | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.20% | 9.30% | -2.10 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 18.5x | 30.4x | -11.90 | CARR | /valuation <GO> |
| Free Cash Flow Yield | 3.35% | 2.40% | +0.95 | CARR | /fcf-yield <GO> |
| Operating Margin | 10.00% | 17.40% | -7.40 | TMO | /operating-margins <GO> |
| Net Profit Margin | 6.80% | 15.10% | -8.30 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | -3.30% | 3.90% | -7.20 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.69% | 0.24% | +1.45 | CARR | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.47 | 4.50 | -2.03 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.70% | +0.20 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.3 | 59.1 | -21.82 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.94 | +0.06 | CARR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.7x | 36.3x | -7.60 | CARR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $45.78B | $262.22B | -$216.43B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CARR REV | TMO REV | CARR GROSS % | TMO GROSS % | CARR FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $21.75B | $44.56B | 44.0% | 44.0% | $1.53B | $6.29B |
| FY 2024 | $22.49B | $42.88B | 26.6% | 44.0% | -$448.9M | $7.27B |
| FY 2023 | $18.95B | $42.86B | 44.0% | 44.0% | $1.75B | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CARR // BETA 1.00
TMO // BETA 0.94